John Prendergast

Title: John Prendergast: Innovator in Target Specific Screening

Introduction

John Prendergast is an accomplished inventor based in Lawrenceville, NJ (US). He holds a patent that showcases his innovative approach to target specific screening, which has significant implications in the fields of diagnostics and therapeutics.

Latest Patents

Prendergast's patent, titled "Target specific screening and its use for identifying target binders," relates to a modified phage display method for detecting and identifying target and target binders. This invention involves transforming host cells with two separate phages of a target or target library and a target-binder library. The method selects to eliminate non-paired targets and binders, enhancing the efficiency of the screening process. Additionally, the patent covers antibodies that bind to complexes of target and target binders, nucleic acids encoding target and target binder peptides, and the use of sequence information inherent in the targets and target binders for target validation using in silico approaches. The invention also has applications in small molecule drug discovery, diagnostics, and therapeutics directed towards cancers and similar disorders.

Career Highlights

John Prendergast is currently associated with Antyra Inc., where he continues to contribute to advancements in biotechnological innovations. His work focuses on developing methods that improve the identification and validation of therapeutic targets.

Collaborations

Prendergast collaborates with talented individuals such as Renuka Pillutla and Renee Brissette, who contribute to the innovative environment at Antyra Inc.

Conclusion

John Prendergast's contributions to the field of target specific screening exemplify the impact of innovative thinking in biotechnology. His patent reflects a significant advancement that could lead to improved diagnostic and therapeutic strategies.